Pulmonology

theMednet to Offer CME Credits and MOC Points Through Its User Generated, Online Learning Platform

Retrieved on: 
Thursday, October 6, 2022
Physician, LinkedIn, Pulmonology, Maintenance, Oncology, Continuing medical education, MOC, Accreditation, Academic health science centre, CME, Patient, Indian Medical Association, Rheumatology, Research, Twitter, Hematology, Maintenance of Certification, Partnership, University, NEW, Learning, Neurology, Q&A, CEO, ACCME, Dermatology, Blog, American Medical Association, Accreditation Council, AMA, Chicago (franchise), Accreditation Council for Continuing Medical Education, Center, Medicine, Certification, Facebook

NEW YORK, Oct. 6, 2022 /PRNewswire/ -- theMednet, the leading, physician-only platform that provides expert answers to complex questions and real-world clinical situations, announces its physician members can now receive up to 20 Continuing Medical Education (CME) credits and Maintenance of Certification (MOC) points annually through its knowledge-sharing platform. theMednet is a free and easily accessible resource which provides physicians with qualified answers to questions that have not been addressed by guidelines or published research. The platform's internet-point-of-care learning activities have been implemented in accordance with the Accreditation Council for Continuing Medical Education (ACCME) guidelines through the joint providership of the University of Chicago Pritzker School of Medicine and theMednet.

Key Points: 
  • "theMednet was created to help physicians communicate through an online, medical platform to reduce health disparities among patients around the US," said Samir Housri, co-founder and CEO of the theMednet.
  • In recent years, there has been a push for providers to offer more ways to receive CME credits.
  • theMednet is a free, online Q&A resource for physicians to pose clinical questions and get answers from experts through cited data and clinical experience.
  • In addition to its web-based community forum, theMednet has an app, a blog , and offers a daily newsletter for physicians.

Apnimed Expands Senior Leadership Team by Appointing John Cronin, M.D., Senior Vice President, Clinical Development

Retrieved on: 
Wednesday, October 5, 2022
Biotechnology, Pharmaceutical, Health, Other Health, Quality of life, LinkedIn, Respironics, Pulmonology, CA, Hypertension, Sleep apnea, Georgetown University, Cardiovascular disease, Risk, Population, Stroke, Drug, CPAP, Obstructive sleep apnea, Patient, Mass General Brigham, Critical care, Relaxation, Research, Twitter, Multimedia, Senior, Coronavirus Scientific Advisory Board (Turkey), Medical director, Medical Affairs Bureau, Industry, Airway obstruction, Diabetes, FDA, Central nervous system, Duke University, Pharmaceutical industry, Sleep, Mass

Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for obstructive sleep apnea and related disorders, today announced that John Cronin, M.D., has joined the company as Senior Vice President, Clinical Development.

Key Points: 
  • Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for obstructive sleep apnea and related disorders, today announced that John Cronin, M.D., has joined the company as Senior Vice President, Clinical Development.
  • He will contribute immediately to the development and execution of clinical strategy for AD109, Apnimeds most advanced clinical candidate for obstructive sleep apnea (OSA), as well as help to enhance Apnimeds Medical Affairs team.
  • View the full release here: https://www.businesswire.com/news/home/20221005005126/en/
    Apnimed expands senior leadership team by appointing John Cronin, M.D., Senior Vice President, Clinical Development (Photo: Business Wire)
    John is a proven industry and clinical leader with deep experience and understanding of our therapeutic area, and we are excited to welcome him to the Apnimed team, said Larry Miller, M.D., Chief Executive Officer of Apnimed.
  • AD109 is currently completing Phase 2 clinical trials, after which Apnimed plans to meet with the FDA to discuss the Phase 3 development program.

Beyond Cancer™ to Present Pre-Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2022 SITC Annual Meeting

Retrieved on: 
Wednesday, October 5, 2022
U.S. Securities and Exchange Commission, Society for Immunotherapy of Cancer, Time, Nitric oxide, Urinary tract infection, Atmosphere of Earth, UNO, Pulmonary hypertension, SITC, Pulmonology, Boston Convention and Exhibition Center, Policy, NASDAQ, Annual report, Patient, NO, Security (finance), Nontuberculous mycobacteria, Immunotherapy, NTM, Technology, Convention center, Respiratory distress syndrome, Company, Hypoxemia, Society, Toxicity, Wilms' tumor, Adult, Safety, GLOBE, Radiation, Forward-looking statement, Ultra, Death, FDA, COVID-19, Pharmaceutical industry, Medical imaging, Cancer

Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc., is a development-stage biopharmaceutical and medical device company utilizing ultra-high concentration nitric oxide (UNO) via a proprietary delivery platform to treat primary tumors and prevent metastatic disease.

Key Points: 
  • Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc., is a development-stage biopharmaceutical and medical device company utilizing ultra-high concentration nitric oxide (UNO) via a proprietary delivery platform to treat primary tumors and prevent metastatic disease.
  • Nitric oxide at ultra-high concentrations has been reported to show anticancer properties and to potentially serve as a chemosensitizer and radiotherapy enhancer.
  • Ultra-high concentration Nitric Oxide (UNO) therapy is a completely new approach to preventing relapse or metastatic disease.
  • In vitro murine data show that local tumor ablation with UNO stimulates an anti-tumor immune response in solid tumor cancer models.

Beyond Air® Announces that Annals of the American Thoracic Society Published a Review of the Third Pilot Study of High Dose Nitric Oxide for Bronchiolitis

Retrieved on: 
Monday, October 3, 2022
RSV, Review, Annals of the American Thoracic Society, Respiratory syncytial virus, COVID-19, Annual report, Nitric oxide, ATS, Policy, ITT, NO, FTD, Pulmonary hypertension, TAL, Marketing, UNO, PH, American Thoracic Society, VCAP, NASDAQ, Pulmonology, Fungus, NTM, Degenerative disease, Atmosphere of Earth, Respiratory distress syndrome, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, SST, Artery, Manuscript, Nontuberculous mycobacteria, HR, Hospital, Adult, Time, Parasitism, Physician, SEC, Food, Hypoxemia, FDA, Mycobacterium, Urinary tract infection, NO2, Forward-looking statement, Risk, Company, GLOBE, Community-acquired pneumonia, Virus, Bronchiolitis, Bacteria, Union, Pharmaceutical industry, Vaccine

The manuscript in the Annals of the American Thoracic Society is available at (https://doi.org/10.1513/AnnalsATS.202103-348OC).

Key Points: 
  • The manuscript in the Annals of the American Thoracic Society is available at (https://doi.org/10.1513/AnnalsATS.202103-348OC).
  • This multicenter, double-blind, randomized-controlled study enrolled 89 patients under the age of 12 months who were hospitalized with moderate-severe bronchiolitis.
  • The patients were randomized equally across three arms: standard supportive therapy (SST); 85 ppm NO + SST and 150 ppm NO + SST.
  • The primary endpoint was time to fit-to-discharge (FTD), a composite of the modified TAL score and sustained oxygen saturation on room air.

RS BioTherapeutics Secures $3 Million Seed II Round of Funding

Retrieved on: 
Monday, September 26, 2022
ECS, Marshall University, SARS-COV-2, Pulmonology, IND, Asthma, Growth, Endocannabinoid system, RS, Degenerative disease, Dark Seed II, Lung, Research, COPD, Cystic fibrosis, Bronchitis, GLOBE, Synthon

CUMBERLAND, Md., Sept. 26, 2022 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness its strong and thorough understanding of the endocannabinoid system (ECS) to research, develop and commercialize interventions to address chronic and acute pulmonary (lung) inflammation-based diseases, is pleased to announce that is has secured a $3 million Seed II round of funding.

Key Points: 
  • CUMBERLAND, Md., Sept. 26, 2022 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness its strong and thorough understanding of the endocannabinoid system (ECS) to research, develop and commercialize interventions to address chronic and acute pulmonary (lung) inflammation-based diseases, is pleased to announce that is has secured a $3 million Seed II round of funding.
  • In July, RS BioTherapeutics announced positive results from its proof-of-concept study with its development partner Synthonics and Marshall University, for its first investigational compound, RSBT-001.
  • Commenting on the raise, Justin Molignoni, Chief Strategy Officer of RS BioTherapeutics said, Closing this round of funding is an exciting milestone which will help accelerate the growth of the company.
  • Founded by experts in pulmonary diseases and the endocannabinoid system, RS BioTherapeutics is a wholly owned subsidiary of Real Science Holdco LLC.

Wake Up Narcolepsy Physician Survey Shows Significant Challenges in Successful Diagnosis of Narcolepsy

Retrieved on: 
Thursday, September 22, 2022
Pediatrics, Time, Safety, Department, CHESS, REM, Biomarker, Hospital, Knowledge, Neurology, Wakefulness, Population, MSLT, Digital Insight, Idiopathic hypersomnia, Boston Children's Hospital, Patient, WUN, Physician, Pulmonology, NREM, PSG, Hallucination, Cataplexy, Multiple Sleep Latency Test, Advance for NPs & PAs, Diagnosis, Harvard Medical School, Sleep, Mixed anxiety–depressive disorder, Associate, Research, Somnolence, Neurological disorder, Sleep paralysis, Overalls, FTI Consulting, Awareness, Education, Pharmaceutical industry, Insomnia, Narcolepsy, Greater Boston, Polysomnography

WORCESTER, Mass., Sept. 22, 2022 /PRNewswire/ -- Wake Up Narcolepsy (WUN), a national leader for narcolepsy research and awareness, today announced the results of a survey of 100 physicians who treat narcolepsy in children and adolescents in the Greater Boston Area. These findings, which coincide with World Narcolepsy Day, highlight the challenges of identifying, managing and treating narcolepsy in this patient population.

Key Points: 
  • These findings, which coincide with World Narcolepsy Day , highlight the challenges of identifying, managing and treating narcolepsy in this patient population.
  • "These survey results are illuminating, as they highlight improved physician knowledge about narcolepsy compared to previously published data.
  • There are two main types of narcolepsy: narcolepsy with cataplexy (Type 1) and narcolepsy without cataplexy (Type 2).
  • Wake Up Narcolepsy (WUN) is a 501(c)(3) not-for-profit organization founded in 2008 to promote narcolepsy research and awareness.

EQS-News: Atriva Therapeutics announces Topline Results from the Proof of Concept (POC) / Phase 2a RESPIRE study (zapnometinib) in patients hospitalized with COVID-19

Retrieved on: 
Tuesday, September 20, 2022
Adult, Safety, World, POC, Global, Respiratory Medicine, Tablet, Trial of the century, Incidence, Projection, COVID-19, Odds ratio, ODD, Panther, FDA, Prevalence, Orthornavirae, Food, Severe acute respiratory syndrome coronavirus 2, CSS, Respiratory syncytial virus, Therapy, Patient, Program, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, RSV, Viral load, MEK, Standard of care, Orthohantavirus, Cell, Pulmonology, Omicron, Data, Degenerative disease, WHO, RNA, Patent, Death, Hepatotoxicity, Medical imaging, Pharmaceutical industry, Vaccine, Delta

Patients enrolled in RESPIRE were well balanced between groups, with 40% of patients requiring supplemental oxygen in the zapnometinib arm and 41% requiring supplemental oxygen in the placebo arm.

Key Points: 
  • Patients enrolled in RESPIRE were well balanced between groups, with 40% of patients requiring supplemental oxygen in the zapnometinib arm and 41% requiring supplemental oxygen in the placebo arm.
  • Safety data from RESPIRE indicate a favorable profile, with a balanced incidence of treatment-emergent adverse events (TEAEs) between study groups.
  • Dr. Stephan Stenglein, CMO Atriva Therapeutics, adds: We are pleased to see impressive data from our first clinical study (RESPIRE).
  • RESPIRE1 is a randomized, double-blind, placebo-controlled, international, multi-center POC (Proof of Concept) / Phase 2 clinical trial in adult patients with moderate-to-severe COVID-19.

Beyond Air® To Participate in Three Upcoming Investor Conferences

Retrieved on: 
Friday, September 16, 2022
Time, COVID-19, Policy, Risk, FDA, Nitric oxide, Pulmonology, Company, Forward-looking statement, Patient, PH, Physician, Annual report, Urinary tract infection, Atmosphere of Earth, Conference, SEC, Union, Nontuberculous mycobacteria, Hospital, Marketing, NO, NTM, Pulmonary hypertension, Pharmaceutical industry

The Company has received FDA approval for its first system, LungFit PH, for persistent pulmonary hypertension of the newborn.

Key Points: 
  • The Company has received FDA approval for its first system, LungFit PH, for persistent pulmonary hypertension of the newborn.
  • Additionally, Beyond Cancer, an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting.
  • Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made.
  • We undertake no obligation to update, and we do not have a policy of updating or revising, these forward-looking statements, except as required by applicable law.

AdaptHealth Capital Markets Day to Highlight Progress Executing Strategy to Transform Healthcare by Keeping Patients Healthy at Home

Retrieved on: 
Friday, September 16, 2022
Medical Supplies, Medical Devices, Health, Other Health, Managed Care, General Health, Income, Probability, Efficiency, COVID-19, Oxygen, GAAP, PAP, EBITDA, Nature, Company, Acquisition, Compliance, Growth, Capital market, Review, Obstructive sleep apnea, Diabetes, U.S. Securities and Exchange Commission, Forward-looking statement, CPAP, Patient, Stoma, Pulmonology, Event, Solution, Adjustment, Coronavirus, Private Securities Litigation Reform Act, NASDAQ, Security (finance), Incontinence, HME, Hospital, Management, Risk management, Bank, Medicare, Medicaid

“We are proud to showcase the tremendous progress we have made in building an organization that delivers essential, cost-effective care and helps enable our more than 3.9 million patients to live their best lives, healthy at home,” said Griggs. “Through acquisitions, organic investments, and operational excellence, we have repositioned AdaptHealth with valuable scale, operating leverage, and value creation potential for patients, payors, providers, and shareholders. Today, we are well-positioned with a tech-enabled patient first care model, a broad portfolio of market-leading sleep, respiratory and diabetes solutions, world-class compliance, and a growing network of touchpoints into the patient’s home -- including 36,000 daily deliveries, 650 patient advocate sales reps, and over 1,000 AdaptHealth healthcare professionals.”

Key Points: 
  • Through acquisitions, organic investments, and operational excellence, we have repositioned AdaptHealth with valuable scale, operating leverage, and value creation potential for patients, payors, providers, and shareholders.
  • By leveraging our established foundation and executing on our ongoing growth and efficiency priorities, we are positioning AdaptHealth to drive toward our new three-year financial goals.
  • AdaptHealth is a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services.
  • The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this press release.

The Future of Chiropractic Imaging Arrives with the FDA Clearance of Dynamic Digital Radiography on the Chiropractic Straight Arm

Retrieved on: 
Thursday, September 15, 2022
Digital radiography, PACS, Workflow, Clinical research, Time, Imaging, Efficiency, Movement, FDA, CSA, Research, Musculoskeletal injury, Pulmonology, Radiography, Acquisition, Injury, Whiplash, Patient, Intelligence, Konica Minolta, Technology, DDR, Solution, Diagnosis, Doctor of Philosophy, Motion, Podiatry, GLOBE, Health care, CRYSTAL, Anatomy, Medical imaging

CRYSTAL LAKE, Ill., Sept. 15, 2022 (GLOBE NEWSWIRE) -- 20/20 Imaging , a division of Konica Minolta Healthcare Americas, Inc ., announces the FDA clearance of the Chiropractic Straight Arm (CSA) system with Dynamic Digital Radiography (DDR) .

Key Points: 
  • CRYSTAL LAKE, Ill., Sept. 15, 2022 (GLOBE NEWSWIRE) -- 20/20 Imaging , a division of Konica Minolta Healthcare Americas, Inc ., announces the FDA clearance of the Chiropractic Straight Arm (CSA) system with Dynamic Digital Radiography (DDR) .
  • The combination of the advanced imaging of the CSA with DDR will further enhance the diagnosis and management of musculoskeletal conditions.
  • DDR is not fluoroscopy; it is a series of individual digital images acquired at high speed and low dose.
  • 20/20 Imaging, a division of Konica Minolta Healthcare, is a value-added reseller of Healthcare IT, and digital imaging solutions tailored for specialties such as podiatry and chiropractic medicine.